Kurs
-0,91%
Likviditet
56,0 MDKK
Kalender
| Tid* | ||
| 2025-08-12 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-03-06 | N/A | Årsstämma |
| 2025-02-05 | 07:30 | Bokslutskommuniké 2024 |
| 2024-08-14 | - | Kvartalsrapport 2024-Q2 |
| 2024-03-07 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2024-03-06 | - | Årsstämma |
| 2024-02-06 | - | Bokslutskommuniké 2023 |
| 2023-08-15 | - | Kvartalsrapport 2023-Q2 |
| 2023-03-09 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2023-03-08 | - | Årsstämma |
| 2023-02-07 | - | Bokslutskommuniké 2022 |
| 2022-08-16 | - | Kvartalsrapport 2022-Q2 |
| 2022-03-11 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2022-03-10 | - | Årsstämma |
| 2022-02-08 | - | Bokslutskommuniké 2021 |
| 2021-08-12 | - | Kvartalsrapport 2021-Q2 |
| 2021-03-08 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2021-03-05 | - | Årsstämma |
| 2021-02-09 | - | Bokslutskommuniké 2020 |
| 2020-08-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-03-11 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2020-03-10 | - | Årsstämma |
| 2020-02-04 | - | Bokslutskommuniké 2019 |
| 2019-08-14 | - | Kvartalsrapport 2019-Q2 |
| 2019-03-20 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2019-03-19 | - | Årsstämma |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-08-15 | - | Kvartalsrapport 2018-Q2 |
| 2018-03-23 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2018-03-22 | - | Årsstämma |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-08-14 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-09 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-28 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2017-03-27 | - | Årsstämma |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-17 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | - | Split DEMANT 1:5 |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-08 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2016-04-07 | - | Årsstämma |
| 2016-03-01 | - | Bokslutskommuniké 2015 |
| 2015-11-12 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-14 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-10 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2015-04-09 | - | Årsstämma |
| 2015-02-26 | - | Bokslutskommuniké 2014 |
| 2014-11-13 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-14 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-10 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2014-04-09 | - | Årsstämma |
| 2014-02-27 | - | Bokslutskommuniké 2013 |
| 2013-11-05 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-14 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-07 | - | Kvartalsrapport 2013-Q1 |
| 2013-04-10 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2013-04-09 | - | Årsstämma |
| 2013-02-26 | - | Bokslutskommuniké 2012 |
| 2012-11-07 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-16 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-10 | - | Kvartalsrapport 2012-Q1 |
| 2012-04-12 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2012-04-11 | - | Årsstämma |
| 2012-02-29 | - | Bokslutskommuniké 2011 |
| 2011-11-10 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-19 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-12 | - | Kvartalsrapport 2011-Q1 |
| 2011-04-14 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
| 2011-04-13 | - | Årsstämma |
| 2010-11-16 | - | Kvartalsrapport 2010-Q3 |
| 2010-04-08 | - | X-dag ordinarie utdelning DEMANT 0.00 DKK |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
16.9.2024 10:30:08 CEST | Demant A/S | Investor News
Investor news | 16 September 2024 |
New President of Diagnostics and member of Demant Management
Effective 1 November 2024, Anne-Karen Hunt will join Demant and take up the position as President of Demant’s Diagnostics business area. René Schneider, who concurrently with his role as CFO of Demant, has held the position as interim President since April 2023, will help ensure a proper transition when Anne-Karen Hunt joins the company.
Anne-Karen Hunt has spent the last 20 years of her career in various international medical technology companies, most recently in GE HealthCare where she held the position as General Manager and President of the Ultrasound International business of the EMEA, APAC and LATAM regions.
Besides taking on the responsibility for the Diagnostics business area, Anne-Karen Hunt will join Demant Management and thus take part in driving Demant’s strategy forward.
“I am looking forward to welcoming Anne-Karen Hunt as new President of Diagnostics and member of the Demant Management. Anne-Karen Hunt is a strong profile and a strategic thinker, who has successfully led large, international organisations with a proven track record of business development and performance. She has a collaborative leadership mindset and focuses on creating trust in high-performing teams.
She is the right profile for leading our Diagnostics business area into the future, and I am sure she will do great things in collaboration with the many talented people in our Diagnostics business and across Demant,” says Søren Nielsen, President and CEO in Demant.
Anne-Karen Hunt is of German nationality. Her educational background is in marketing and economics, and she holds an MBA from the University of Düsseldorf.
“I am excited to join Demant. The combination of a company truly committed to hearing healthcare, a strong purpose of making life-changing differences and a long track record of profitable growth is very interesting to me. During my career, I have always been focused on understanding the customer needs as the foundation for building business strategy, and I look forward to getting to know the Diagnostics business further and contributing to its ongoing development and success,” says Anne-Karen Hunt.
Curriculum vitae – Anne-Karen Hunt
2023 – now: GE HealthCare
- General Manager and President – Ultrasound International (EMEA, APAC, LATAM)
- General Manager and President – Imaging (EMEA)
2017-2023: Abbott
- Divisional VP Commercial – Abbott Cardiac Rhythm Management (EMEA)
- Divisional VP Commercial – Abbott Heart Failure (AMERICAS)
- International Head & General Manager – Neuromodulation (EMEA & APAC)
2002-2017: Various positions with Terumo Interventional Systems and Johnson & Johnson
Further information: Søren Nielsen, President & CEO Phone +45 3917 7300 | Other contacts: René Schneider, CFO Peter Pudselykke, Head of Investor Relations Henrik Axel Lynge Buchter, Manager of External Communications |
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.